Top ▲

CD52

Click here for help

Target id: 2602

Nomenclature: CD52

Family: CD molecules

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 61 1p36.11 CD52 CD52 molecule
Mouse - 74 4 66.5 cM Cd52 CD52 antigen
Rat - 96 5q36 Cd52 CD52 molecule
Previous and Unofficial Names Click here for help
CAMPATH-1 antigen | myeloid cell surface antigen CD33
Database Links Click here for help
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Pharos
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia

Download all structure-activity data for this target as a CSV file go icon to follow link

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
alemtuzumab Peptide Approved drug Primary target of this compound Immunopharmacology Ligand Hs Binding - - 1-2
[1-2]
Antibody Comments
The anti-CD52 antibody GZ-402668 (GLD52; gatralimab) was developed by Sanofi for the treament of progressive multiple sclerosis. Having completed Phase 1 evaluation, Sanofi halted further development of this agent in early 2018.
Immunopharmacology Comments
CD52 (CAMPATH-1) is a short, glycosylphosphatidylinositol (GPI) anchored peptide expressed on lymphocytes and by cells of the male genital tract. CD52 is required for complement-mediated cell lysis and antibody-mediated cellular cytotoxicity. The approved monoclonal antibody, alemtuzumab targets this function of CD52. By attaching to sperm it may be associated with oocyte penetration and fertilisation.
Cell Type Associations
Immuno Cell Type:  Macrophages & monocytes
Cell Ontology Term:   monocyte (CL:0000576)
macrophage (CL:0000235)
Immuno Cell Type:  Natural killer cells
Immuno Cell Type:  B cells
Immuno Cell Type:  T cells

References

Show »

1. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D. (1998) Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res., 22 (2): 185-91. [PMID:9593475]

2. Shitara K, Niwa R, Natsume A. (2011) Recombinant antibody composition. Patent number: US7923538 B2. Assignee: Kyowa Hakko Kirin Co., Ltd. Priority date: 22/07/2005. Publication date: 12/04/2011.

How to cite this page

CD molecules: CD52. Last modified on 22/10/2019. Accessed on 24/11/2020. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=2602.